Guidance for Industry

Risk Evaluation and Mitigation Strategies: Modifications and Revisions

U.S. Department of Health and Human Services,  Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)

April 2015

This guidance provides information on how the FDA will define and process submissions from application holders for modifications and revisions to approved risk evaluation and mitigation strategies (REMS). Specifically, this guidance provides information on what types of changes to REMS will be considered modifications of the REMS, as described in section 505-1(h) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), and what types of changes will be considered revisions of the REMS. There are different procedures for submission of REMS  modifications and revisions to the FDA, as well as different time frames for FDA review and action on such changes. This guidance provides information on how REMS modifications and revisions should be submitted to the FDA, and the FDA’s process for reviewing and acting on these submissions. The definitions of REMS modifications and revisions set forth in this 30 guidance apply to all types of REMS. This guidance is issued pursuant to sections 505­ 1(h)(2)(A)(ii), (iii), and (iv) of the FD&C Act.  

This guidance does not address additional procedures that may apply to application holders proposing changes to REMS that are part of a single shared system. The FDA intends to address these procedures in future guidance.  

The information contained in this guidance pertaining to REMS modification and revision submission procedures for application holders and the time frames for the FDA review and action supersedes the information on the same topic contained in the draft guidance for industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications. 

Download “Risk Evaluation and Mitigation Strategies: Modifications and Revisions” ucm441226.pdf – Downloaded 421 times – 635 KB

Global Compliance Seminar (GCS) provides global and FDA regulatory consulting and training services to the FDA-regulated industry in collaboration with the Regulatory Doctor. The US FDA is an Agency under the US Department of Health and Human Services (DHHS).

Risk Evaluation and Mitigation Strategies, Modifications and Revisions